Hello,
Welcome to
- We compared the four health insurance upstarts that have gone public this year;
- Why a top biotech analyst thinks an activist investor is getting one big thing wrong about GSK;
- Vaccinated health officials are still wearing masks indoors amid the spread of the Delta variant.
If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...
4 hot health-insurer upstarts have gone public this year. Only one is trading up.
- Four of five closely watched health-insurer upstarts have gone public in 2021.
- Each went public with big valuations, even though they are all unprofitable.
Here's how they've performed in the stock market so far>>
An activist investor has one big thing wrong about pharma giant GlaxoSmithKline, according to a top Wall Street analyst
- The activist investor Elliott Management is pushing for change at the pharma giant GlaxoSmithKline.
- Among its suggestions, Elliott wants
GSK to invest more in its internal R&D efforts. - Industry analyst Geoffrey Porges said M&A and share buybacks are better options.
Vaccinated US health experts are wearing masks indoors as the Delta variant spreads
- The CDC says if you're fully vaccinated, you do not need to wear your mask indoors in public.
- But many leading health experts are still being cautious, masking around others when they don't know their status.
- Vaccines still work well against severe cases of the Delta variant, but many experts say "why take the risk" of even a mild case?
More stories we're reading:
- Pfizer's COVID-19 vaccine is less effective at preventing Delta infections than other variants, but still protects against severe illness, preliminary Israeli study says (Insider)
- Dr. Eric Topol argues it's time for the FDA to fully approve Pfizer/BioNTech's and Moderna's vaccines (The New York Times)
- Johnson & Johnson says its COVID-19 vaccine should work against the Delta variant, citing 2 small studies (Insider)
- EQT and Goldman are buying contract-research organization Parexel in an $8.5 billion deal (The Wall Street Journal)
- Lydia